PT Indofarma Tbk (ISX:INAF) Piotroski F-Score: 5 (As of Aug. 11, 2026) — 25% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISX:INAF PT Indofarma Tbk ISX:INAF
8 GF Score
Price Rp126.00
GF Value Rp176.99
! 6 Warning Signs
View Full Analysis

What is PT Indofarma Tbk Piotroski F-Score?

PT Indofarma Tbk ISX:INAF 8 Piotroski F-Score is 5 as of Aug. 11, 2026, which is 25% above its 10-year median of 4.00. GuruFocus rates ISX:INAF with a GF Score™ of 8/100 and a GF Value™ of Rp176.99. The stock has 6 warning signs investors should review.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PT Indofarma Tbk has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for PT Indofarma Tbk's Piotroski F-Score or its related term are showing as below:

ISX:INAF' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 7
Current: 5

During the past 13 years, the highest Piotroski F-Score of PT Indofarma Tbk was 7. The lowest was 1. And the median was 4.

PT Indofarma Tbk  (ISX:INAF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


PT Indofarma Tbk Piotroski F-Score Related Terms


PT Indofarma Tbk Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for PT Indofarma Tbk's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Indofarma Tbk Piotroski F-Score Chart

PT Indofarma Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 2.00 3.00 4.00 4.00

PT Indofarma Tbk Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 4.00 4.00 5.00

ISX:INAF vs ZTS, VTRS, NBIX: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PT Indofarma Tbk's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Indofarma Tbk Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PT Indofarma Tbk's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where PT Indofarma Tbk's Piotroski F-Score falls into.


ISX:INAF
8GF Score
PT Indofarma Tbk ISX:INAF
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Net Income was -83538.977 + 49101.768 + -7580.466 + -25549.616 = Rp-67,567 Mil.
Cash Flow from Operations was -162165.224 + -30631.814 + 6231.636 + -4318.334 = Rp-190,884 Mil.
Revenue was 66706.653 + 17815.307 + 53325.349 + 25718.564 = Rp163,566 Mil.
Gross Profit was -1614.112 + -7642.13 + 4747.518 + 3170.623 = Rp-1,338 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(559641.829 + 581558.305 + 535988.243 + 489667.151 + 510834.388) / 5 = Rp535537.9832 Mil.
Total Assets at the begining of this year (Jun25) was Rp559,642 Mil.
Long-Term Debt & Capital Lease Obligation was Rp472,088 Mil.
Total Current Assets was Rp100,095 Mil.
Total Current Liabilities was Rp657,668 Mil.
Net Income was -64543.724 + -168006.302 + -25109.244 + -18442.844 = Rp-276,102 Mil.

Revenue was 28151.964 + 72509.255 + 36762.049 + 30266.533 = Rp167,690 Mil.
Gross Profit was -13134.919 + -25706.102 + -5603.272 + -4357.344 = Rp-48,802 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(821463.739 + 758434.103 + 617768.889 + 574079.237 + 559641.829) / 5 = Rp666277.5594 Mil.
Total Assets at the begining of last year (Jun24) was Rp821,464 Mil.
Long-Term Debt & Capital Lease Obligation was Rp215,409 Mil.
Total Current Assets was Rp129,983 Mil.
Total Current Liabilities was Rp1,109,238 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PT Indofarma Tbk's current Net Income (TTM) was -67,567. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PT Indofarma Tbk's current Cash Flow from Operations (TTM) was -190,884. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun25)
=-67567.291/559641.829
=-0.1207331

ROA (Last Year)=Net Income/Total Assets (Jun24)
=-276102.114/821463.739
=-0.33610992

PT Indofarma Tbk's return on assets of this year was -0.1207331. PT Indofarma Tbk's return on assets of last year was -0.33610992. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

PT Indofarma Tbk's current Net Income (TTM) was -67,567. PT Indofarma Tbk's current Cash Flow from Operations (TTM) was -190,884. ==> -190,884 <= -67,567 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun25 to Jun26
=472088.494/535537.9832
=0.88152196

Gearing (Last Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=215408.76/666277.5594
=0.32330184

PT Indofarma Tbk's gearing of this year was 0.88152196. PT Indofarma Tbk's gearing of last year was 0.32330184. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun26)=Total Current Assets/Total Current Liabilities
=100095.117/657667.744
=0.15219709

Current Ratio (Last Year: Jun25)=Total Current Assets/Total Current Liabilities
=129983.277/1109237.808
=0.11718252

PT Indofarma Tbk's current ratio of this year was 0.15219709. PT Indofarma Tbk's current ratio of last year was 0.11718252. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

PT Indofarma Tbk's number of shares in issue this year was 3099.268. PT Indofarma Tbk's number of shares in issue last year was 3099.268. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=-1338.101/163565.873
=-0.00818081

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=-48801.637/167689.801
=-0.29102329

PT Indofarma Tbk's gross margin of this year was -0.00818081. PT Indofarma Tbk's gross margin of last year was -0.29102329. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun25)
=163565.873/559641.829
=0.29226885

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun24)
=167689.801/821463.739
=0.20413537

PT Indofarma Tbk's asset turnover of this year was 0.29226885. PT Indofarma Tbk's asset turnover of last year was 0.20413537. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+0+1+1+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PT Indofarma Tbk has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
PT Indofarma Tbk (ISX:INAF) has a Piotroski F-Score of 5 as of Aug. 11, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on PT Indofarma Tbk and its competitors. This is 25% above median its historical median of 4.00. Over the past decade, PT Indofarma Tbk's Piotroski F-Score has ranged from 1.00 to 7.00.
Is PT Indofarma Tbk's Piotroski F-Score too high?
PT Indofarma Tbk's current Piotroski F-Score of 5 is 25% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. PT Indofarma Tbk's value of 5 is 0% at this industry median. Overall, PT Indofarma Tbk has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does PT Indofarma Tbk's Piotroski F-Score compare to ZTS and VTRS?
PT Indofarma Tbk's Piotroski F-Score of 5 can be compared against companies in the Drug Manufacturers industry. The industry median Piotroski F-Score is 5.00. PT Indofarma Tbk's value of 5 is 0% at this benchmark. Historically, PT Indofarma Tbk's own Piotroski F-Score has ranged from 1.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, PT Indofarma Tbk has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 977 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Indofarma Tbk's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on PT Indofarma Tbk and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Indofarma Tbk's current Piotroski F-Score is 5, which is 25% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Indofarma Tbk stock overvalued right now?
PT Indofarma Tbk (ISX:INAF) has a current Piotroski F-Score of 5. The stock's GF Value™ is Rp176.99, compared to a current price of Rp126.00 — trading 28.8% below its estimated fair value. The current Piotroski F-Score is 5, which is 25% above median its 10-year median of 4.00 and 0% at the Drug Manufacturers industry median of 5.00. PT Indofarma Tbk's overall GF Score™ is 8/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For PT Indofarma Tbk (ISX:INAF), the current Piotroski F-Score is 5 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Indofarma Tbk (ISX:INAF) Overvalued in 2026?

Based on GuruFocus' analysis, PT Indofarma Tbk stock appears to be undervalued. The current stock price of Rp126.00 is trading 28.8% below its estimated GF Value™ of Rp176.99.

Key valuation signals for ISX:INAF:

  • Piotroski F-Score: 5 (25% above median its 10-year median of 4.00)
  • GF Value™: Rp176.99 vs. price of Rp126.00 (28.8% below fair value)
  • GF Score™: 8/100 with 6 warning signs
  • Industry Position: 0% at the Drug Manufacturers median

No single metric tells the full story. See the ISX:INAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PT Indofarma Tbk Business Description

Address Jalan Indofarma No. 1, Cikarang Barat, Jawa Bara, Bekasi, IDN, 17530
PT Indofarma Tbk is a specialty and generic drug manufacturing company. The company has four business segments - Medicine, Medical Devices and others. The Medicine business segment includes drug production, marketing distribution, and sales. The Medical Device Segment includes medical devices and other products. Company generates majority revenue from the Medicine segment. The Company classifies its distribution segments based on geographic regions into six areas, namely Java, Sumatra, Kalimantan, Sulawesi, Bali dan West Nusa Tenggara (NTB),as well as the Eastern Indonesia region.
8GF Score

Get the complete analysis for ISX:INAF

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp126.00
Price
Rp176.99
GF Value